BIOFRONTERA AG/ADR (NASDAQ:BFRA) Given $21.75 Consensus Price Target by Analysts

Shares of BIOFRONTERA AG/ADR (NASDAQ:BFRA) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $21.75 for the company, according to Zacks. Zacks has also assigned BIOFRONTERA AG/ADR an industry rank of 48 out of 256 based on the ratings given to related companies.

Separately, Lake Street Capital decreased their price objective on BIOFRONTERA AG/ADR from $24.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, July 10th.

Shares of NASDAQ:BFRA remained flat at $$15.35 on Monday. The stock had a trading volume of 62 shares, compared to its average volume of 417. BIOFRONTERA AG/ADR has a twelve month low of $11.04 and a twelve month high of $18.32. The company’s 50-day moving average price is $16.81. The company has a debt-to-equity ratio of 1.56, a current ratio of 3.84 and a quick ratio of 3.38.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last announced its earnings results on Wednesday, May 29th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The firm had revenue of $7.73 million for the quarter. BIOFRONTERA AG/ADR had a negative return on equity of 95.81% and a negative net margin of 62.81%.


Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

Featured Article: Using other technical indicators with support levels

Get a free copy of the Zacks research report on BIOFRONTERA AG/ADR (BFRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with's FREE daily email newsletter.